Latest news with #Hologic
Yahoo
3 days ago
- Business
- Yahoo
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
Hologic (HOLX) has been one of the most searched-for stocks on lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this medical device maker have returned +9.9%, compared to the Zacks S&P 500 composite's +6.4% change. During this period, the Zacks Medical - Instruments industry, which Hologic falls in, has gained 2.4%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Hologic is expected to post earnings of $1.06 per share for the current quarter, representing no change from the year-ago quarter. Over the last 30 days, the Zacks Consensus Estimate has changed -4.3%. The consensus earnings estimate of $4.21 for the current fiscal year indicates a year-over-year change of +3.2%. This estimate has changed -1.5% over the last 30 days. For the next fiscal year, the consensus earnings estimate of $4.53 indicates a change of +7.5% from what Hologic is expected to report a year ago. Over the past month, the estimate has changed -2%. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Hologic is rated Zacks Rank #4 (Sell). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth. For Hologic, the consensus sales estimate for the current quarter of $1.01 billion indicates a year-over-year change of -0.4%. For the current and next fiscal years, $4.08 billion and $4.28 billion estimates indicate +1.2% and +5% changes, respectively. Hologic reported revenues of $1.01 billion in the last reported quarter, representing a year-over-year change of -1.2%. EPS of $1.03 for the same period compares with $1.03 a year ago. Compared to the Zacks Consensus Estimate of $1 billion, the reported revenues represent a surprise of +0.34%. The EPS surprise was +0.98%. Over the last four quarters, Hologic surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period. Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Hologic is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on might help determine whether or not it's worthwhile paying attention to the market buzz about Hologic. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
3 days ago
- Business
- Forbes
The WTA And Hologic On Advancing Women's Sports Healthcare
Gaby Dabrowski and Erin Routliffe won the women's doubles title at the Rothesay Open in Nottingham ... More in 2024. The WTA has a proud legacy of prioritizing athlete health, rooted in the vision of the Original 9 and Billie Jean King. Early on, the WTA recognized that simply treating injuries wasn't enough. Female athletes face unique challenges like motherhood and career transitions that demand a proactive, integrated approach to care. Over the years, the WTA has continually evolved to meet these needs, offering support that includes international health coverage, mental health resources, special ranking protections for pregnancy and injury, and on-site access to physicians, physical therapists, and more. In 2022, the WTA took its commitment to athlete health even further through a groundbreaking partnership with Hologic, a global leader in women's health and medical technology. This collaboration is centered on a shared mission: to redefine what wellness looks like for women competing at the highest levels—and to extend those benefits beyond the court. Highlights of this partnership include: WTA Hologic Healthcare, Horizon DXA System Reflecting on her 30 years with the WTA, Kathleen Stroia, the WTA's Senior Vice President of Performance Health, sees the current moment as a turning point—not just for tennis, but for all of women's sports. 'Historically, women's sports medicine has taken a reactive approach,' says Stroia. 'It focused on treating injuries after they occurred. What we've created with Hologic is a proactive, integrated model specifically designed for the unique physiology and life experiences of female athletes.' 'When I started, there was very little data or research on women athletes. Most medical protocols were designed for men and scaled down for us,' she says. 'Today, we're leading with research, innovating with intent, and setting a new gold standard—one where athlete care and performance health go hand in hand.' The WTA offers the most comprehensive annual physicals in women's sports. Players undergo advanced screening that includes DXA scans to assess bone density and body composition, crucial data points that help identify risks early and tailor training regimens accordingly. PARIS, FRANCE - MAY 29: Jessica Pegula of the United States in action against Ann Li of the United ... More States in the second round of the singles competition on Court Philippe-Chatrier during the 2025 French Open Tennis Tournament at Roland Garros on May 29th, 2025, in Paris, France. (Photo by) Just as importantly, the WTA provides dedicated women's health stations at tournaments, giving players convenient access to services that are rarely prioritized in other sports, such as breast and cervical screenings, hormone evaluations, fertility education, and professional bra fittings. 'It's like going to a world-class women's clinic that's built into your career,' says Jessica Pegula, currently ranked among the world's top singles players. 'In one session, I learned more about my hormone levels, bone health, and long-term fertility options than I ever had from years of separate appointments. I walked away with clarity, not just for tennis but for my future as a woman.' RIYADH, SAUDI ARABIA - NOVEMBER 07: Gabriela Dabrowski of Canada hits pink signed tennis balls for ... More breast cancer awareness into the crowd with Erin Routliffe of New Zealand i(out of pic) after their victory against Caroline Dolehide of the United States and Desirae Krawczyk of the United States in their round robin doubles match during Day 6 of the 2024 WTA Finals Riyadh as part of the Hologic WTA Tour at King Saud University Indoor Arena on November 07, 2024 in Riyadh, Saudi Arabia. (Photo by) For Canadian doubles champion Gaby Dabrowski, the WTA's commitment to proactive health screening became deeply personal. 'I had found a lump and mentioned it during my annual WTA physical,' Dabrowski recalls. 'Because of that, they fast-tracked me for a scan and biopsy. That's when I was diagnosed with breast cancer. It was early. And that timing changed everything.' Dabrowski says the medical support from the WTA and the emotional support from Stroia's team carried her through diagnosis, treatment, and recovery. 'They didn't just check the box. They surrounded me with care, experts, counselors, even someone to walk me through nutrition during chemo. Kathleen called me personally to check in. It felt like I had an entire family behind me,' Dabrowski says. 'People think of the WTA as a sports organization, but at that moment, they were my healthcare lifeline. If I had waited or ignored it, my story might have been very different.' Dabrowski has since returned to the tour and is sharing her story to encourage other athletes and fans to advocate for their health. 'Early detection saved my life. Every woman deserves access to that.' WTA Hologic Health Screening 2024 According to Stroia, one of the keys to the WTA's success has been its commitment to listening to players and responding in real time. 'Our athletes are not just recipients of care, they're co-creators,' she explains. 'Whether it's about mental health, maternity leave, or injury recovery, we take their input and build policies and services that reflect their realities.' This player-driven approach led to the 2019 overhaul of the Special Ranking Rule, championed by Serena Williams and Victoria Azarenka, to better protect rankings for athletes returning from maternity leave or injury. It's also influenced the expansion of mental health resources, including a dedicated mental health care team that travels to major tournaments and provides virtual support year-round. 'Mental health is just as important as physical health, especially in a sport where you're constantly on the road and under pressure,' says Pegula. 'Having access to licensed professionals who understand the demands of the tour has been a game-changer for so many of us.' The WTA has worked to remove barriers by streamlining access to specialists and empowering athletes with knowledge. From nutritionists and sleep experts to injury-prevention research and on-demand telehealth, the infrastructure now reflects a holistic approach to peak performance. NEW YORK, NEW YORK - SEPTEMBER 09: Blair Henley speaks at the ceremony honoring the induction of the ... More Original 9 into the International Tennis Hall of Fame on Day Eleven of the 2021 US Open at the USTA Billie Jean King National Tennis Center on September 09, 2021 in the Flushing neighborhood of the Queens borough of New York City. (Photo) The WTA's groundbreaking approach to women's athlete health is more than a model for tennis, it's a blueprint for women's sports. By combining cutting-edge science, player-driven policies, and compassionate care, they're proving that investing in women's health is both the right thing to do and smart business. As Kathleen Stroia puts it, 'Athlete care is performance care.' With expanded health screenings, mental health resources, fertility support, and innovative partnerships like the one with Hologic, the WTA raised the bar for what athlete wellness truly means. Stories like Gaby Dabrowski's show how proactive care can be lifesaving, while ongoing initiatives empower players to shape their own health journeys. This holistic, forward-thinking model doesn't just support elite athletes, it has the power to transform health standards for all women athletes. The WTA's commitment ensures that comprehensive, equitable women's health services are no longer a dream but the new standard and a legacy that will continue to inspire the future of women's sports worldwide.
Yahoo
4 days ago
- Business
- Yahoo
Why Hologic, Inc. (HOLX) Went Up On Tuesday
We recently published a list of . In this article, we are going to take a look at where Hologic, Inc. (NASDAQ:HOLX) stands against other best-performing stocks. Hologic ended a three-day losing streak on Tuesday, jumping 14.54 percent to finish at $62.17 apiece following news that it is being targeted for acquisition for $16 billion. A report by Financial Times on Tuesday said that private equity firms TPG and Blackstone made an approach to acquire Hologic, Inc. (NASDAQ:HOLX). However, the latter was said to have rejected the non-binding offer. If talks resume, the proposed deal would value Hologic, Inc. (NASDAQ:HOLX) between $70 and $72, a significant premium to its $62.17 closing price on Tuesday. In the second quarter of fiscal year 2025, Hologic, Inc. (NASDAQ:HOLX) swung to a net loss of $17.4 million from a $169.9 million net income in the same period last year. A doctor using a medical imaging system to diagnose a patient at a hospital. Revenues dipped by 1 percent to $1.005 billion from $1.017 billion year-on-year. In the six-month period alone, net income dropped by 56 percent to $183.6 million from $416.4 million, while revenues ended flat at $2.03 billion. Overall, HOLX ranks 6th on our list of best-performing stocks. While we acknowledge the potential of HOLX, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HOLX and that has 10,000x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
4 days ago
- Business
- Yahoo
Zimmer hires former Nevro CEO Kevin Thornal
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Name: Kevin Thornal New title: Group president for global businesses and the Americas, Zimmer Biomet Previous title: President and CEO, Nevro Zimmer Biomet named Kevin Thornal to the newly created position of group president for global businesses and the Americas, effective July 1, the orthopedics device maker said Tuesday. Thornal was president and CEO of spinal cord stimulation company Nevro from April 2023 until it was acquired by Globus Medical last month for about $250 million. Before that, he was group president of global diagnostic solutions at Hologic, where he held a series of leadership positions beginning in 2014. Before joining Hologic, Thornal worked in sales, marketing and business development at Stryker for 10 years, including as head of North American sales for its interventional spine business. In his new role, Thornal will oversee the Americas commercial organization and lead business strategy and execution for the global knees, hips, S.E.T. and data, technology and enabling solutions units. Thornal will receive an annual base salary of $850,000, with a bonus opportunity in 2025 equal to 100% of his salary on a prorated basis, if performance goals are achieved, Zimmer said in a securities filing. He will also receive restricted stock units valued at $2.65 million and performance-based restricted stock units valued at $2.65 million. In connection with Thornal's appointment, Mark Bezjak will remain president of the Americas but will no longer be an executive officer, according to the filing. Bezjak was promoted to president of the Americas from president of North America in September 2023, shortly after CEO Ivan Tornos became Zimmer's top executive.
Yahoo
5 days ago
- Business
- Yahoo
Why Hologic, Inc. (HOLX) Went Up On Tuesday
We recently published a list of . In this article, we are going to take a look at where Hologic, Inc. (NASDAQ:HOLX) stands against other best-performing stocks. Hologic ended a three-day losing streak on Tuesday, jumping 14.54 percent to finish at $62.17 apiece following news that it is being targeted for acquisition for $16 billion. A report by Financial Times on Tuesday said that private equity firms TPG and Blackstone made an approach to acquire Hologic, Inc. (NASDAQ:HOLX). However, the latter was said to have rejected the non-binding offer. If talks resume, the proposed deal would value Hologic, Inc. (NASDAQ:HOLX) between $70 and $72, a significant premium to its $62.17 closing price on Tuesday. In the second quarter of fiscal year 2025, Hologic, Inc. (NASDAQ:HOLX) swung to a net loss of $17.4 million from a $169.9 million net income in the same period last year. A doctor using a medical imaging system to diagnose a patient at a hospital. Revenues dipped by 1 percent to $1.005 billion from $1.017 billion year-on-year. In the six-month period alone, net income dropped by 56 percent to $183.6 million from $416.4 million, while revenues ended flat at $2.03 billion. Overall, HOLX ranks 6th on our list of best-performing stocks. While we acknowledge the potential of HOLX, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HOLX and that has 10,000x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
